Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pathogenesis of psoriatic arthritis

Dafna D Gladman, MD, FRCPC
Christopher Ritchlin, MD, MPH
Section Editor
Joachim Sieper, MD
Deputy Editor
Paul L Romain, MD


The precise causes of psoriasis and psoriatic arthritis (PsA) have not been identified. It seems likely, however, that genetic, immunologic, and environmental factors all contribute [1]. It is also reasonable to assume that the skin and joint diseases have a similar pathogenesis, although the activity of these manifestations does not highly correlate in individual patients. (See "Clinical manifestations and diagnosis of psoriatic arthritis".)


Psoriasis has long been known to occur in families. The possible role of genetic factors is illustrated by the following observations [2-5]:

Approximately 40 percent of patients with psoriasis or psoriatic arthritis (PsA) have a family history of these disorders in first-degree relatives [6].

Family studies in PsA have demonstrated that the disease is 55 times more likely to occur among first-degree relatives than among unrelated controls [7]. A significantly increased risk of PsA among first-degree relatives of patients with PsA has also been described [8]. The concordance rate for PsA is much higher than that for psoriasis (30 versus 7 percent) [9].

There is greater concordance for psoriasis among monozygotic twins than among dizygotic twins [10]. One study of twin pairs with at least one patient with PsA found a similar rate of concordance for PsA in monozygotic and dizygotic twins, arguing against a strong role for a heritable component for PsA, but the results in this relatively small study were imprecise and not conclusive [10].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 5, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Barnas JL, Ritchlin CT. Etiology and Pathogenesis of Psoriatic Arthritis. Rheum Dis Clin North Am 2015; 41:643.
  2. de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol 2014; 94:627.
  3. O'Rielly DD, Rahman P. Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis. Rheum Dis Clin North Am 2015; 41:623.
  4. Eder L, Chandran V, Gladman DD. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr Opin Rheumatol 2015; 27:91.
  5. FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther 2015; 17:115.
  6. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13:586.
  7. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64 Suppl 2:ii37.
  8. Myers A, Kay LJ, Lynch SA, Walker DJ. Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology (Oxford) 2005; 44:773.
  9. Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009; 68:664.
  10. Pedersen OB, Svendsen AJ, Ejstrup L, et al. On the heritability of psoriatic arthritis. Disease concordance among monozygotic and dizygotic twins. Ann Rheum Dis 2008; 67:1417.
  11. Pollock RA, Thavaneswaran A, Pellett F, et al. Further Evidence Supporting a Parent-of-Origin Effect in Psoriatic Disease. Arthritis Care Res (Hoboken) 2015; 67:1586.
  12. Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol 1999; 60:259.
  13. Eder L, Chandran V, Pellet F, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis 2012; 71:50.
  14. Gladman DD, Farewell VT, Rahman P, et al. HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. Hum Immunol 2001; 62:1239.
  15. Korendowych E, Dixey J, Cox B, et al. The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol 2003; 30:96.
  16. Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998; 25:730.
  17. Giardina E, Hüffmeier U, Ravindran J, et al. Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis Rheum 2011; 63:3801.
  18. Winchester R, Minevich G, Steshenko V, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2012; 64:1134.
  19. Haroon M, Winchester R, Giles JT, et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 2016; 75:155.
  20. Queiro R, Morante I, Cabezas I, Acasuso B. HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology (Oxford) 2016; 55:221.
  21. Sakkas LI, Marchesoni A, Kerr LA, et al. Immunoglobulin heavy chain gene polymorphisms in Italian patients with psoriasis and psoriatic arthritis. Br J Rheumatol 1991; 30:449.
  22. Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264:1141.
  23. Martin MP, Nelson G, Lee JH, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 169:2818.
  24. Chandran V, Bull SB, Pellett FJ, et al. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology (Oxford) 2014; 53:233.
  25. Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995; 38:845.
  26. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6:813.
  27. Veal CD, Clough RL, Barber RC, et al. Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 2001; 38:7.
  28. Gladman DD, Farewell VT, Pellett F, et al. HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. Hum Immunol 2003; 64:887.
  29. Allen MH, Veal C, Faassen A, et al. A non-HLA gene within the MHC in psoriasis. Lancet 1999; 353:1589.
  30. Oka A, Tamiya G, Tomizawa M, et al. Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum Mol Genet 1999; 8:2165.
  31. Nair RP, Stuart P, Henseler T, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 2000; 66:1833.
  32. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41:199.
  33. Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012; 132:593.
  34. Ellinghaus E, Stuart PE, Ellinghaus D, et al. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol 2012; 132:1133.
  35. Karason A, Gudjonsson JE, Upmanyu R, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 2003; 72:125.
  36. Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42:991.
  37. Stuart PE, Nair RP, Tsoi LC, et al. Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Am J Hum Genet 2015; 97:816.
  38. Budu-Aggrey A, Bowes J, Barton A. Identifying a novel locus for psoriatic arthritis. Rheumatology (Oxford) 2016; 55:25.
  39. Rahman P, Bartlett S, Siannis F, et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet 2003; 73:677.
  40. Giardina E, Novelli G, Costanzo A, et al. Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population. J Invest Dermatol 2004; 122:1106.
  41. Lascorz J, Burkhardt H, Hüffmeier U, et al. Lack of genetic association of the three more common polymorphisms of CARD15 with psoriatic arthritis and psoriasis in a German cohort. Ann Rheum Dis 2005; 64:951.
  42. Ho P, Bruce IN, Silman A, et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005; 52:3596.
  43. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012; 90:784.
  44. Docampo E, Giardina E, Riveira-Muñoz E, et al. Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: a study in Spanish and Italian populations and meta-analysis. Arthritis Rheum 2011; 63:1860.
  45. Rahman P, Siannis F, Butt C, et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006; 65:919.
  46. Reich K, Hüffmeier U, König IR, et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007; 56:2056.
  47. Balding J, Kane D, Livingstone W, et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003; 48:1408.
  48. Höhler T, Grossmann S, Stradmann-Bellinghausen B, et al. Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis. Ann Rheum Dis 2002; 61:213.
  49. Gonzalez S, Martinez-Borra J, Torre-Alonso JC, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 1999; 42:1010.
  50. González S, Brautbar C, Martínez-Borra J, et al. Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol 2001; 62:632.
  51. Pollock RA, Pellett FJ, Chandran V, Gladman DD. Expression patterns of natural killer receptor genes in inflamed joints and peripheral blood of patients with psoriatic arthritis. Tissue Antigens 2011; 78:345.
  52. Rahman P, Butt C, Siannis F, et al. Association of SEEK1 and psoriatic arthritis in two distinct Canadian populations. Ann Rheum Dis 2005; 64:1370.
  53. Butt C, Peddle L, Greenwood C, et al. Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study. Arthritis Res Ther 2006; 8:R27.
  54. Rahman P, Sun S, Peddle L, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006; 54:2321.
  55. Rahman P, Inman RD, Maksymowych WP, et al. Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol 2009; 36:137.
  56. Filer C, Ho P, Smith RL, et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008; 58:3705.
  57. Hüffmeier U, Lascorz J, Böhm B, et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 2009; 129:355.
  58. Butt C, Sun S, Greenwood C, et al. Lack of association of SLC22A4, SLC22A5, SLC9A3R1 and RUNX1 variants in psoriatic arthritis. Rheumatology (Oxford) 2005; 44:820.
  59. Hüffmeier U, Traupe H, Burkhardt H, et al. Lack of evidence for genetic association to RUNX1 binding site at PSORS2 in different German psoriasis cohorts. J Invest Dermatol 2005; 124:107.
  60. Bowes J, Ho P, Salah S, et al. IL-13 is a risk locus for psoriatic arthritis but not psoriasis vulgaris. Arthritis Rheum 2010; 62:S348.
  61. Eder L, Chandran V, Pellett F, et al. The association of IL-13 polymorphism with psoriatic arthritis among psoriasis patients. Arthritis Rheum 2010; 62:S830.
  62. Gladman DD. Toward unraveling the mystery of psoriatic arthritis. Arthritis Rheum 1993; 36:881.
  63. McGonagle D, Ash Z, Dickie L, et al. The early phase of psoriatic arthritis. Ann Rheum Dis 2011; 70 Suppl 1:i71.
  64. Panayi GS. Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol 1994; 8:419.
  65. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24:518.
  66. van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65:1551.
  67. Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007; 46:417.
  68. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25:1544.
  69. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7:R569.
  70. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155:145.
  71. Costello P, Bresnihan B, O'Farrelly C, FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999; 26:1117.
  72. Tassiulas I, Duncan SR, Centola M, et al. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999; 60:479.
  73. Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014; 66:1272.
  74. Leijten EF, van Kempen TS, Boes M, et al. Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid. Arthritis Rheumatol 2015; 67:2673.
  75. Villanova F, Flutter B, Tosi I, et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol 2014; 134:984.
  76. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012; 359:419.
  77. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010; 62:2876.
  78. Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med 2013; 19:822.
  79. McQueen FM, Skinner MA, Krissansen GW, et al. Natural killer cell function and expression of beta 7 integrin in psoriatic arthritis. J Rheumatol 1994; 21:2266.
  80. Companjen A, van der Wel L, van der Fits L, et al. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. Eur Cytokine Netw 2004; 15:210.
  81. Rooney T, Murphy E, Benito M, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 2004; 63:1393.
  82. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821.
  83. Beyer C, Schett G. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage. Best Pract Res Clin Rheumatol 2010; 24:489.
  84. Neumüller J, Dunky A, Burtscher H, et al. Interaction of monocytes from patients with psoriatic arthritis with cultured microvascular endothelial cells. Clin Immunol 2001; 98:143.
  85. Hitchon CA, Danning CL, Illei GG, et al. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. J Rheumatol 2002; 29:107.
  86. McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56:2482.
  87. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012; 18:1069.
  88. Benjamin M, Toumi H, Suzuki D, et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum 2007; 56:224.
  89. Prinz JC. Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26:326.
  90. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol 2012; 188:5160.
  91. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol 2011; 9:244.
  92. Scarpa R, Del Puente A, di Girolamo C, et al. Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis. Ann Rheum Dis 1992; 51:78.
  93. Pattison E, Harrison BJ, Griffiths CE, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 2008; 67:672.
  94. Soltani-Arabshahi R, Wong B, Feng BJ, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 2010; 146:721.
  95. Eder L, Loo T, Chandran V, et al. Environmental risk factors for psoriatic arthritis among patients with psoriasis: A case-control study. Arthritis Rheum 2010; 62:S809.
  96. Eder L, Shanmugarajah S, Thavaneswaran A, et al. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2012; 71:219.